Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 130,561

Document Document Title
WO/2018/082034A1
Disclosed herein is a novel use of a triterpenoid mixture for the treatment of multiple sclerosis (MS). The triterpenoid mixture consists of, ganoderic acid A (GAA), ganoderic acid B (GAB), ganoderic acid C (GAC), ganoderic acid C5 (GAC5...  
WO/2018/085803A1
Disclosed herein are pyrido[3',2':4,5]thieno[2,3-d]pyridazin-8-amine and thieno[2,3-c:4,5-d']dipyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Als...  
WO/2018/085521A3
The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.7 and other voltage-gated sodium channel subtypes, such as pain, in particular neuropathic pain, most particularly trig...  
WO/2018/082814A1
The invention relates to 5-amino-2,3-dihydro-1,4-phthalazinedione or related compounds, compositions or combinations thereof, for use in the treatment of chronic progressive multiple sclerosis, in particular primary and secondary progres...  
WO/2018/083098A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/083171A1
The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.  
WO/2018/083697A1
The invention generally concerns and methods of using glatiramer acetate (GA) and cannabidiol (CBD), for treating, preventing, ameliorating or delaying MS, and side effects associated with MS treatment.  
WO/2018/085486A9
Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering fr...  
WO/2018/085521A9
The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.7 and other voltage-gated sodium channel subtypes, such as pain, in particular neuropathic pain, most particularly trig...  
WO/2018/083051A1
The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairm...  
WO/2018/082557A1
Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for prep...  
WO/2018/083247A1
The present invention relates to 4,4a,5,7-tetrahydro-3H-furo[3,4-b]pyridinyl compound inhibitors of beta-site APP-cleaving enzyme having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The inv...  
WO/2018/085476A1
The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering fr...  
WO/2018/083101A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/083695A3
The invention generally concerns methods and formulations utilized in the methods which comprise cannabis plant extracts and copaxone.  
WO/2018/083050A1
The present invention relates to a compound of formula I, 1-1 or 1-2 wherein R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, or lower alkoxy substituted by halogen; R1may be different if n = 2 or 3...  
WO/2018/083223A1
The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.  
WO/2018/085486A1
Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering fr...  
WO/2018/083103A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/085263A1
Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that can metabolize under physiological conditions to ornithine. The pH and plasma stability of compounds of formula (II...  
WO/2018/081018A1
A method is disclosed of treating pain with senicapoc, a potent Ca2+- activated K+ channel, Kca3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-Ιβ and NO release from microglia cells vivo and in...  
WO/2018/076090A1
The present invention relates to novel and inventive pharmacologically active benzimidazole derivative compounds, which surprisingly have high affinity for melatonin MTi and MT2 receptors and low affinity for CYP450 complex enzymes f spe...  
WO/2018/079693A1
Provided are: a pharmaceutical for preventing and/or treating symptoms of depression, the pharmaceutical comprising (S)-norketamine or a pharmacologically acceptable salt thereof; a pharmaceutical composition for preventing and/or treati...  
WO/2018/081777A1
Provided herein are methods of treating or preventing a neurodegenerative disease in a subject using an inhibitor of discoidin domain receptor (DDR) tyrosine kinase.  
WO/2018/081614A1
Disclosed here is a method for enhancing synaptogenesis and/or neurogenesis, reducing neurodegeneration, and/or reducing accumulation or aggregation of Tau proteins in a subject suffering from cochlear synaptopathy or vestibular synaptop...  
WO/2018/081251A1
The present invention provides methods for the prevention or treatment of Parkinson's Disease using Abelson-family tyrosine kinase inhibitors.  
WO/2018/081761A1
Transdermal patches and transdermally applyable pharmaceutical compositions containing an effective amount of at least one drug are disclosed. The at least one drug may be: (a) phenmetrazine; (b) 4-benzylpiperidine; (c) 3-flouroamphetami...  
WO/2018/079628A1
The present invention provides: a compound which is useful as a therapeutic agent for diseases associated with metabolic glutamic acid receptor subtype 2 (mGluR2), and which is represented by formula (1) [in formula (1), -X-ring B repres...  
WO/2018/076783A1
The present invention provides a crystalline form of dextral oxiracetam. The crystalline form has a diffraction peak when a diffraction angle, 2θ, is 17.76±0.2°, 20.16±0.2°, 21.20±0.2°, 24.17±0.2°, or 25.88±0.2°. The crystalli...  
WO/2018/080917A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, (I) Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compoun...  
WO/2018/081175A1
Systems and methods for recommending foods to a user based on health data, includes a database, a memory and a processor. The database stores user health data for each user within a plurality of users, including vitals, genotypic and phe...  
WO/2018/077310A1
Disclosed is a vitamin C sodium-containing effervescent tablet, comprising the following components in parts by weight: 200-1120 parts of vitamin C sodium, 560-1300 parts of tartaric acid, 600-1500 parts of sodium bicarbonate, and 200-60...  
WO/2018/080918A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds o...  
WO/2018/077212A1
Disclosed is a nanobody preparation system for administration through the internal and external epidermis of head and neck and the internal epidermal layer of nasal cavity, comprising a specific nanobody having a biological activity and ...  
WO/2018/081825A1
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the...  
WO/2018/079734A1
A medicinal composition which is in the form of granules, a powder or a preparation for syrup comprising memantine or a pharmaceutically acceptable salt thereof and an enteric polymer, said composition being easy to ingest even for aged ...  
WO/2018/080916A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds o...  
WO/2018/079695A1
An inhibitor for cognitive function decline or an improver for learning ability is provided. The inhibitor for cognitive function decline or the improver for learning ability contains, as an active ingredient, a liver hydrolysate having ...  
WO/2018/076782A1
The present invention provides a crystalline form of dextral oxiracetam. The crystalline form has a diffraction peak when a diffraction angle, 2θ, is 17.12±0.2°, 18.88±0.2°,19.24±0.2°, 21.18±0.2°, or 24.88±0.2°. The crystallin...  
WO/2018/078038A1
The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attent...  
WO/2018/079631A1
Provided is a preventive agent which is for a growing child's anxiety, attributable to stress in infancy, and which is to be taken by an infant who has stress in infancy. Provided is a preventive agent for a growing child's anxiety, attr...  
WO/2018/081294A1
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors of formula 1 and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The di...  
WO/2018/076107A1
In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof minocycline, or a functional derivative thereof, and hydroxychloroquine, or a fun...  
WO/2018/078010A1
The present invention relates to polysubstituted quinic acid derivatives (abbreviated to "PSQs") of general formula (IA): in which R represents a linear or branched, cyclic or branched cyclic, saturated or unsaturated C2-Cp alkyl group, ...  
WO/2018/079862A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1, R2, R3 and n are as defined in the specification, a process for their preparation, pharmaceutical compositions containing t...  
WO/2018/078042A1
The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disea...  
WO/2018/081590A1
The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.  
WO/2018/080573A1
Provided herein are methods for identifying genetic networks and methods of treating neurodegenerative disorders associated with α-synuclein dysfunction.  
WO/2018/079693A9
Provided are: a pharmaceutical for preventing and/or treating symptoms of depression, the pharmaceutical comprising (S)-norketamine or a pharmacologically acceptable salt thereof; a pharmaceutical composition for preventing and/or treati...  
WO/2018/078631A1
Methods for predicting antidepressant treatment response for a subject in need thereof, for predicting resistance to antidepressant treatment, and for generating a predictor of response to antidepressant treatment, are provided.  

Matches 401 - 450 out of 130,561